Some news to talk about today with interesting implications and I will try to cover most of them. The sector seems to be lagging early despite some business development news but we also had a big miss by BIIB that might be acting as a headwind (the M&A rumor seem to save the day so […]
April 22 Biotech Update
Another busy day so I have to keep this very short as I am trying to squeeze this in between meetings. In general, the sector seems to be doing fine and modestly outperforming the market. It remains to be seen if this is a sustainable move or whether it is a bounce from new M&A […]
April 21 Biotech Update
A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to the ideas over the next couple of days. In general, the sector is doing well with the deal flow news but I will talk more […]
April 17 Biotech Update
The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was it renewed concerns over a Grexit? You would think by now investors are prepared for that potential and/or have been immunized by these repeated concerns. […]
Catalyst Watch – Vol. 3, Edition 5 (4/17/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: STRIDE trial […]
April 15 Biotech Update
It is a busy day so I am going to try and keep this short but every time I write that it seems like I write the same amount if not more than usual. The sector basically looks in-line with the broader markets and large caps actually seem to be participating in the move higher, […]
Quick Note on GWPH
Embargoed Data was released yesterday in an announcement from AAN regarding GW Pharmaceuticals’ Epidiolex study: https://www.aan.com/PressRoom/Home/PressRelease/1364 This paragraph summarizes the Key Takeaway: “For the 137 people who completed the 12-week study, the number of seizures decreased by an average of 54 percent from the beginning of the study to the end. Among the 23 people […]
April 14 Biotech Update
A weak start to the day that essentially appears to be a continuation from the late selling yesterday. It still seems to be the case that large caps are underperforming the SMID, which has been the case for awhile. I suspect that is going to be a difficult trend to break but for the long […]
April 13 Biotech Update
Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a little that the current expectation is that we will see mergers every Monday as the sector should ideally move on fundamentals and not quick merger […]
April 10 Biotech Update
A good opening to the sector and large caps but the move was almost immediately faded (especially the large caps). Yesterday ended better than the past, so perhaps the sector can recover and regain the lost ground but I still worry about this pattern of strong openings that are continually sold throughout the day. It […]
CYNAF is OFF the Mark
Cynapsus is developing a sublingual film formulation of apomorphine for the treatment of acute “Off” episodes in patients with Parkinson’s Disease resulting from long term use of Levodopa. While Levodopa is considered the single best treatment for Parkinson’s, long term use of the medicine leads to motor fluctuations as its efficacy declines. Patients then begin […]
April 9th Biotech Update
The market is choppy this morning so it is difficult to read anything into the price action. I am growing slightly more constructive on the near term of the sector but that is a very low conviction view. While the sector bounced on support, I have a hard time believing that the sell off was […]
April 8 Biotech Update
It was actually a good morning for the sector with large and SMID caps doing well. While that is a good first step, we need these moves to not only stick but strengthen at the end of the day. Another fade would indicate that the selling pressure remains a headwind. The sector is in an […]
April 6 Biotech Update
I have not had a chance to follow the market last week, so I do not really have a sense how the sector is doing. It looks like it has been more of the same with weakness and large caps trudging along and unable to generate any real leadership. The sector is certainly lagging the […]
Catalyst Watch – Vol. 3, Edition 4 (4/3/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
BMY – Is the Technical Correction Done ?
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high $69.20 in March, 20th 2015, getting a boost from the fastest FDA approval I ever seen. On Febreuary 27th 2015 the FDA granted Priority Review […]
March 31 Biotech Update
The sector was relatively weak yesterday and did not start this morning particular strong. I still am noticing the large cap lagging trend that has been going on for awhile. Is this simply a function of the lack of near term catalysts, increasing bearishness on the large caps, investors chasing returns lower on the capital […]
March 30 Biotech Update
It looks like we have all survived the great biotech sell off of 2015. To be honest, I am not sure this really counts as a sell off (yet). We have been spoiled by the steady march higher and while this is a nice bounce, we were also very oversold in the short term. Add […]
March 27 Biotech Update
The sector is in bounce mode. While I certainly think there is room for a rally after the sharp selling, I would not read this as an all clear. Yes, the downdraft took some of the overvalued names down pretty far but this seems too orderly and easy for it to be done. Obviously, we […]
